Previous 10 | Next 10 |
2023-12-18 12:03:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alzamend Neuro (NASDAQ: ALZN ) just reported results for the second quarter of 2024. Alzamend Neuro reported earnings per share of -44 cents. The company did not repor...
2023-12-11 09:15:25 ET More on Alzamend Neuro Alzamend stock tumbles 18% in wake of clinical study update Alzamend Neuro stock plummets on 1-for-15 reverse stock split Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend...
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for ...
Lanvin Group Holdings Limited (LANV) is expected to report for quarter end 2023-09-30 Sonnet BioTherapeutics Holdings Inc. (SONN) is expected to report for Q4 2023 Shionogi & Co. Ltd. ADR (SGIOY) is expected to report for Q2 2024 Gelesis Holdings, Inc. (GLSHQ) is expected to repor...
2023-11-21 13:33:17 ET More on Alzamend Neuro Alzamend Neuro stock plummets on 1-for-15 reverse stock split Alzamend Neuro granted extension by Nasdaq panel Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend Neuro ...
2023-11-21 09:59:42 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
2023-11-21 08:16:38 ET Losers: Morphosys AG ( MOR ) -24% . Sibanye Stillwater Limited ( SBSW ) -23% . reAlpha Tech Corp. ( AIRE ) -14% . Alzamend Neuro ( ALZN ) -16% . American Eagle Outfitters AEO -13% after Q3 earning release ....
2023-11-20 12:59:05 ET Gainers: Mira Pharmaceuticals ( MIRA ) +58% . YPF ADR ( YPF ) +39% . Altamira Therapeutics Ltd ( CYTO ) +39% . ProKidney Corp ( PROK ) +35% . Soluna Holdings ( SLNH ) +32% . Safety Shot ( SHOT ) +...
Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring Safety aspects of AL001 development may qualify for ...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), m...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC (AZN) is expected to report $0.97 for Q2 2024 BJ's Restaurants Inc. (BJRI) is expected to report $0.49 for Q2 2024 Baker Hughes Company (BKR) is expected to report $0.49 for Q2 2024 BlueHarbor Bank (BLHK) is expected to report for Q2 2024 Betterware de Mexico S.A.P...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...